Core Insights - IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a potential best-in-class PRMT5 inhibitor targeting MTAP-deleted solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [1] - The company plans to deprioritize combination activities with Trodelvy to focus on its proprietary MTAP-deleted and CDKN2A pipeline, aiming for a first-in-class CDKN2A development candidate nomination in H2 2026 and an IND submission in H1 2027 [1] Group 1: IDE892 Development - The first patient has been enrolled in the Phase 1 trial evaluating IDE892, which will assess safety, tolerability, pharmacokinetics, and pharmacodynamics as a monotherapy and in combination with IDE397 [1] - IDE892 exhibits approximately 1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes and demonstrates single-digit nanomolar potency in MTAP-deleted cell lines [1] - Preclinical studies show that dual inhibition of PRMT5 and MAT2A with IDE892 and IDE397 resulted in durable tumor regressions in MTAP-deleted tumor models [1] Group 2: CDKN2A Program - IDEAYA is advancing its CDKN2A-deficiency program, targeting a first-in-class development candidate selection in H2 2026 and an IND submission in H1 2027 [1] - CDKN2A deficiency is prevalent in over 80% of pancreatic cancer cases and is often co-deleted with MTAP, creating opportunities for rational combination therapies [1] - The company has demonstrated robust monotherapy efficacy with its CDKN2A lead in multiple preclinical models, including a KRAS mutation pancreatic model [1] Group 3: Strategic Prioritization - As part of its strategic focus, IDEAYA has deprioritized clinical combination activities with Trodelvy and will conclude enrollment in ongoing Phase 1/2 trials with Gilead [1] - The company may explore additional combinations between IDE397 and other TOP1 payload ADCs, including IDE034, in the context of MTAP-deleted cancers [1] - MTAP deletion occurs in 15-20% of NSCLC, up to 40% of pancreatic cancer, and approximately 15% of all solid tumors, highlighting the unmet need for targeted therapies [1]

Summary of IDEAYA Biosciences Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Clinical-stage precision medicine oncology - **Key Programs**: Nine clinical programs, with a focus on uveal melanoma and other oncology indications Key Points and Arguments Upcoming Catalysts - **Darovasertib**: Lead molecule for uveal melanoma, with an upcoming top-line data release for the combination with crizotinib in metastatic uveal melanoma expected by the end of March 2026. The company has triggered the required 130 events for analysis [2][5] - **Neoadjuvant and Adjuvant Studies**: Enrollment in a neoadjuvant study is ongoing, with plans to begin an adjuvant study in Q2 2026 [3][4] Clinical Data Expectations - **Control Arm Expectations**: The control arm is expected to show a median progression-free survival (PFS) of 2-3 months and overall survival (OS) of about 13 months based on historical data [9][10] - **Darovasertib and Crizotinib Combination**: Previous data indicated a median PFS of about 7 months and OS of 21 months, significantly better than standard therapies [10][12] - **Response Rates**: Standard therapies show a response rate of around 10%, while the combination therapy has shown a response rate exceeding 30% [10] Study Design and Patient Demographics - The study focuses on HLA-A2 negative patients with metastatic uveal melanoma, comparing the combination therapy to standard care, which varies by region [8][9] - The study design includes frequent patient scans every six weeks, which may lead to earlier detection of progression compared to traditional three-month scans [15] Regulatory and Filing Timelines - **FDA Filing**: The company anticipates a six-month timeline to file for accelerated approval post-data release, with a review period of at least six months [30] - **HLA-A2 Positive Group**: Data from HLA-A2 positive patients will be presented in two chapters, with the first chapter expected to show early efficacy data [31][32] Other Pipeline Developments - **DLL3 TOPO1 ADC**: Currently in phase I studies, with initial data expected by the end of 2026. The U.S. study has launched, and early safety data is anticipated [47][48] - **MTAP Inhibitor IDE397**: Ongoing studies in combination with Trodelvy for MTAP-deleted urothelial cancer, with promising early data [59][60] - **Combination Strategies**: The company is exploring various combination therapies, including those targeting PRMT5 and CDKN2A, to enhance treatment efficacy in MTAP-deficient tumors [66][68] Market Position and Future Outlook - IDEAYA aims to set a new standard for uveal melanoma treatment, addressing a significant unmet medical need with limited existing therapies [22][14] - The company has a strong cash position of approximately $1.05 billion, providing a runway into 2030, positioning it well for upcoming clinical milestones [5] Additional Important Information - The company emphasizes the importance of data integrity and the potential for positive outcomes based on historical performance metrics [12][26] - Discussions with the FDA regarding potential label expansions and real-world data integration are ongoing, particularly for HLA-A2 positive patients [33] This summary encapsulates the key points discussed during the conference call, highlighting IDEAYA Biosciences' strategic focus on advancing its oncology pipeline and addressing critical patient needs in uveal melanoma and other cancer indications.

Core Insights - IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapeutics for specific patient populations using molecular diagnostics [1] - The company has promising product candidates, including IDE397 and IDE196, currently in various stages of clinical trials, alongside a strong preclinical pipeline targeting synthetic lethality programs [1] Price Target Trends - The consensus price target for IDEAYA Biosciences has fluctuated, decreasing from an average of $54.67 a quarter ago to $45 in the past month, which is similar to the target from a year ago at $44 [2] - Analysts from Robert W. Baird have set a price target of $18, reflecting the potential of the company's extensive portfolio and near-term catalysts [5] Lead Asset and Revenue Potential - The lead asset, darovasertib, is aimed at treating uveal melanoma and has shown promising results in Phase 2 trials, with potential peak revenue exceeding $500 million [3] - The success of darovasertib could significantly impact the company's financial performance and stock valuation [3] Strategic Partnerships - IDEAYA has established strong partnerships, including one with Servier and collaborations with major pharmaceutical companies like GlaxoSmithKline plc, which are crucial for accelerating drug development [4] - These partnerships may influence analyst sentiment and price targets moving forward [4]

January 2026 Improving Lives Through Transformative Precision Medicines JPM 2026 | 44th Annual Healthcare Conference NASDAQ: IDYA Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, perfor ...

Summary of IDEAYA Biosciences FY Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology Key Points Lead Program: Darovasertib - **Current Status**: In first-line registrational study for metastatic uveal melanoma - **Upcoming Milestones**: Randomized median progression-free survival (PFS) results expected by year-end 2025, with full enrollment for median overall survival (OS) component nearly complete, targeting over 450 patients [2][3][4] - **Breakthrough Therapy Designation**: Received for a phase 3 randomized neoadjuvant trial, which is now active with patients in screening [3][4] Patient Journey in Uveal Melanoma - **Lack of Approved Therapies**: No systemic approved therapies in neoadjuvant or adjuvant settings, with most metastatic patients also lacking approved options [5][6] - **Treatment Options**: Initial treatments include eye resection or plaque therapy, followed by adjuvant phase with no available therapies [7][8] Objectives for Neoadjuvant and Adjuvant Trials - **Primary Endpoint**: Eye preservation rate exceeding 10% with 95% confidence interval for the enucleation cohort [9][10] - **Visual Acuity Goals**: Aim for 20% or more patients in treatment arm passing a 15-letter BCVA vision test [10] DLL3 Topo ADC Program - **Efficacy Data**: Confirmed response rate of 70% in second-line small cell lung cancer at a dose of 2.4 mg/kg [15] - **Safety Profile**: Grade three or higher adverse events (AEs) below 20%, indicating potential for dose escalation [16] Future Development Plans - **Focus Areas**: Small cell lung cancer and neuroendocrine tumors (NETs) with plans to share more data in 2026 [20][23] - **MAT2A and MTAP Pathway**: Ongoing phase two trials for IDE397 (MAT2A inhibitor) and phase one for PRMT5 inhibitor, with updates expected in the first half of next year [24][25] Bispecific ADC Development - **B7-H3 and PTK7**: First-in-class bispecific ADC targeting co-expressed antigens in various tumor types, including non-small cell lung cancer and colorectal cancer [32][34] - **Patient Population**: Approximately one-third of lung cancer patients and 40%-50% of colorectal cancer patients are expected to express both antigens [34] Key Takeaways - **Upcoming Focus**: Randomized PFS results are critical for transitioning towards commercialization [38] - **Overall Strategy**: Emphasis on combination therapies and targeting co-alterations to enhance treatment efficacy [29][30] This summary encapsulates the essential insights from the IDEAYA Biosciences FY Conference Call, highlighting the company's strategic focus, ongoing clinical trials, and future development plans in the oncology sector.

Financial Data and Key Metrics Changes - The company is approaching top line results for its lead program, darovasertib, with guidance for an accelerated approval filing in the U.S. by year-end this year to Q1 next year [3][4] - Historical median progression-free survival (PFS) for metastatic uveal melanoma is about 2-3 months, while the company has reported a PFS of approximately 7 months in its trials, indicating a significant improvement [6][7] Business Line Data and Key Metrics Changes - The company has eight programs in clinical development, with darovasertib being the lead program in a registrational trial for metastatic uveal melanoma [3] - The company has received breakthrough therapy designation for darovasertib in the neoadjuvant setting, indicating a strong pipeline and potential for accelerated development [4] Market Data and Key Metrics Changes - The market for darovasertib targets approximately 4,000-5,000 patients, with a significant portion being HLA negative, which the company aims to address [9] - The annual incidence of neoadjuvant uveal melanoma is estimated to be 10,000-12,000 patients, highlighting a substantial unmet need in this area [12] Company Strategy and Development Direction - The company is focusing on expanding its pipeline in the MTAP deletion space, with a phase two MAT2A inhibitor and a phase one PRMT5 inhibitor, aiming to position itself as a leader in this competitive area [36] - The company is also exploring the DLL3 program for small cell lung cancer, with plans to differentiate based on efficacy and durability compared to competitors [53] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts, particularly for darovasertib, and believes that the combination of strong efficacy data and a robust pipeline will position the company favorably in the market [19][20] - The company is optimistic about the potential for its adjuvant study to become a blockbuster opportunity, targeting patients earlier in their treatment journey [29] Other Important Information - The company is preparing to initiate an adjuvant study in collaboration with Servier, targeting high and high medium metastatic risk populations [27] - The company has a unique bispecific ADC targeting B7-H3 and PTK7, which is expected to amplify efficacy in dual expression populations [66] Q&A Session Summary Question: What is the expected timeline for the neoadjuvant study? - The company anticipates enrolling the study in roughly five quarters, with the first eye preservation data expected in about six months [19][20] Question: How does the company plan to differentiate its DLL3 program? - The company believes it can differentiate based on response rates and durability, leveraging a unique linker system that allows for higher dosing [53][54] Question: What is the competitive landscape for the MTAP deletion space? - The company sees itself as an industry leader in the MTAP deletion area, with a diverse pipeline that includes multiple clinical stage assets [36][37]

Financial Data and Key Metrics Changes - The company is approaching top line results for its lead program, darovasertib, with guidance for an accelerated approval filing in the U.S. by year-end this year to Q1 next year [3][4] - Historical median progression-free survival (PFS) for metastatic uveal melanoma is about 2 to 3 months, while the company has reported a PFS of approximately 7 months in their studies, indicating a significant improvement [6][7] Business Line Data and Key Metrics Changes - The company has eight programs in clinical development, with darovasertib being the lead program in a registrational trial for metastatic uveal melanoma [3] - The company has received breakthrough therapy designation for darovasertib in the neoadjuvant setting, indicating a strong focus on this area [4] - The next key program is DLL3, with recent data presented at the World Conference on Lung Cancer, highlighting its potential in small cell lung cancer [4][55] Market Data and Key Metrics Changes - The market for darovasertib targets approximately 4,000-5,000 patients, with a significant portion being HLA negative, which the company aims to address [9] - The annual incidence of neoadjuvant uveal melanoma is estimated to be 10,000-12,000 patients, indicating a substantial unmet need in this market [12] Company Strategy and Development Direction - The company is focusing on a diversified pipeline, with plans to initiate an adjuvant study in collaboration with Servier in the first half of next year, targeting high-risk metastatic patients [28] - The company aims to implement rational combinations in the MTAP deletion space, positioning itself as a leader in this area with multiple clinical stage assets [37][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts, particularly for eye preservation rates and event-free survival in the neoadjuvant setting [19][13] - The company believes it is well-positioned to address the unmet needs in the neoadjuvant space due to limited competition [15][17] Other Important Information - The company is developing a bispecific ADC targeting B7H3 and PTK7, which is unique in its AND format, aiming to enhance efficacy in dual expression populations [68][69] - The company is also advancing its KAT6/7 inhibitor program, which targets chromatin remodeling, with a focus on breast cancer and potentially other indications [76][77] Q&A Session Summary Question: What is the timeline for the neoadjuvant study? - The company plans to enroll the study in roughly five quarters, with the first eye preservation data expected in about six months [19][20] Question: How does the company plan to differentiate its DLL3 program? - The company believes its linker system allows for higher dosing and reduced toxicity compared to competitors, which could lead to better efficacy and durability [55][56] Question: What is the market potential for the adjuvant study? - The adjuvant market could potentially be the largest of the three indications, with a path to becoming a blockbuster opportunity [30]

Financial Data and Key Metrics Changes - The company is approaching top line results for its lead program, darovasertib, with guidance for an accelerated approval filing in the U.S. by year-end this year to Q1 next year [3][4] - Historical median progression-free survival (PFS) for metastatic uveal melanoma is about 2.5 months, while the company has reported a PFS of approximately 7 months in its trials, indicating a significant improvement [6][8] Business Line Data and Key Metrics Changes - The company has eight programs in clinical development, with darovasertib being the lead program in a registrational trial for metastatic uveal melanoma [3] - The company received breakthrough therapy designation for darovasertib in the neoadjuvant setting, indicating a strong pipeline and potential for accelerated development [4] Market Data and Key Metrics Changes - The target market for darovasertib includes approximately 4,000-5,000 patients, with a significant portion being HLA negative, which the company aims to address [10] - The annual incidence of neoadjuvant uveal melanoma is estimated to be 10,000-12,000 patients, highlighting a substantial unmet need in this area [14] Company Strategy and Development Direction - The company is focusing on expanding its pipeline in the MTAP deletion space, which represents about 10% of all solid tumors, and is pursuing rational combinations to enhance treatment efficacy [39] - The company is also exploring the DLL3 program for small cell lung cancer, aiming to differentiate based on efficacy and durability compared to competitors [57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts, particularly for darovasertib, and highlighted the potential for further upside based on patient baseline characteristics [11][12] - The company is optimistic about the adjuvant study, which is expected to target high-risk populations and could potentially be the largest market segment among its three indications [32] Other Important Information - The company is preparing to initiate an adjuvant study in collaboration with Servier, targeting approximately 450 patients and focusing on relapse-free survival as the primary endpoint [30] - The company is also advancing its KAT6/7 inhibitor program, which aims to enhance activity and durability in cancer treatment [75] Q&A Session Summary Question: What are the expected timelines for the neoadjuvant and adjuvant studies? - The company anticipates eye preservation data in about six months and expects to enroll the neoadjuvant study in roughly five quarters [21][20] Question: How does the company plan to differentiate its DLL3 program? - The company believes its linker system allows for higher dosing and reduced toxicity compared to competitors, which could lead to better efficacy and durability [58] Question: What is the strategy for the MTAP deletion program? - The company aims to implement rational combinations and believes it is an industry leader in this area with multiple clinical stage assets [39]

Core Insights - IDEAYA Biosciences reported significant progress in its pipeline and business operations, including a partnership with Servier that extends its runway into 2030 and enables potential commercialization of darovasertib outside the U.S. [2] Pipeline Developments - The Phase 2/3 trial (OptimUM-02) of darovasertib/crizotinib in metastatic uveal melanoma is on track to report median progression-free survival (PFS) data by year-end 2025 to Q1 2026, with enrollment expected to be completed by year-end [4][5] - The single-arm Phase 2 trial (OptimUM-01) reported a median overall survival (OS) of 21.1 months and a median PFS of 7.0 months, with a confirmed overall response rate (ORR) of 34% [5] - IDEAYA has initiated a randomized Phase 3 trial (OptimUM-10) for darovasertib as a neoadjuvant therapy in primary uveal melanoma, targeting approximately 450 patients [8] Financial Highlights - As of September 30, 2025, IDEAYA had approximately $1.14 billion in cash, cash equivalents, and marketable securities, an increase from $991.9 million as of June 30, 2025, primarily due to a $210 million upfront payment from Servier [11] - Collaboration revenue for Q3 2025 totaled $207.8 million, compared to zero in the previous quarter, driven by the Servier license agreement [11] - The net income for Q3 2025 was $119.2 million, a significant improvement from a net loss of $77.5 million in Q2 2025 [14] License Agreement with Servier - IDEAYA entered into an exclusive license agreement with Servier for darovasertib outside the U.S., receiving an upfront payment of $210 million and being eligible for up to $320 million in milestone payments [10] Research and Development Expenses - R&D expenses for Q3 2025 totaled $83.0 million, an increase from $74.2 million in Q2 2025, primarily due to higher clinical trial and manufacturing expenses [12] General and Administrative Expenses - G&A expenses for Q3 2025 were $16.4 million, up from $14.6 million in Q2 2025, mainly due to increased legal and commercial preparation expenses [13]

Group 1 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as one of the best stocks to buy for the next three months according to hedge funds, with a price target of $41 set by Citizens JMP analyst Ivan Tuerkcan [1] - The company has initiated a Phase 1/2 clinical trial for a combination therapy involving IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy, targeting non-small cell lung cancer (NSCLC) patients with MTAP deletion [2][3] - The trial initially focused on MTAP-deletion urothelial cancer but expanded to include NSCLC in April 2025, conducted in collaboration with Gilead Sciences, which supplies Trodelvy [3]